Total Valuation
Immix Biopharma has a market cap or net worth of $941.46M. The enterprise value is $418.48M.
Market Cap$941.46M
Enterprise Value$418.48M
Share Statistics
Immix Biopharma has 71,539,314 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,539,314
Owned by Insiders17.13%
Owned by Institutions29.56%
Financial Efficiency
Immix Biopharma’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -31.58%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-31.58%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee0.00
Profits Per Employee-1.40M
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immix Biopharma is ―. Immix Biopharma’s PEG ratio is -0.34.
PE Ratio―
PS Ratio0.00
PB Ratio1.84
Price to Fair Value1.84
Price to FCF-6.99
Price to Operating Cash Flow-22.63
PEG Ratio-0.34
Income Statement
In the last 12 months, Immix Biopharma had revenue of 0.00 and earned -29.44M in profits. Earnings per share was -0.89.
Revenue0.00
Gross Profit0.00
Operating Income-29.96M
Pretax Income-29.40M
Net Income-29.44M
EBITDA-29.59M
Earnings Per Share (EPS)-0.89
Cash Flow
In the last 12 months, operating cash flow was -38.50M and capital expenditures -591.11K, giving a free cash flow of -39.09M billion.
Operating Cash Flow-38.50M
Free Cash Flow-39.09M
Free Cash Flow per Share-0.55
Dividends & Yields
Immix Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change523.74%
50-Day Moving Average9.92
200-Day Moving Average7.93
Relative Strength Index (RSI)72.38
Average Volume (3m)2.15M
Important Dates
Immix Biopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immix Biopharma as a current ratio of 10.01, with Debt / Equity ratio of 0.44%
Current Ratio10.01
Quick Ratio10.01
Debt to Market Cap0.00
Net Debt to EBITDA3.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immix Biopharma has paid 37.72K in taxes.
Income Tax37.72K
Effective Tax Rate>-0.01
Enterprise Valuation
Immix Biopharma EV to EBITDA ratio is -2.69, with an EV/FCF ratio of -3.23.
EV to Sales0.00
EV to EBITDA-2.69
EV to Free Cash Flow-3.23
EV to Operating Cash Flow-3.32
Balance Sheet
Immix Biopharma has $232.11M in cash and marketable securities with $1.00M in debt, giving a net cash position of $231.11M billion.
Cash & Marketable Securities$232.11M
Total Debt$1.00M
Net Cash$231.11M
Net Cash Per Share$3.23
Tangible Book Value Per Share$2.85
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immix Biopharma is $19.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.80
Price Target Upside132.39% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-11.21%